Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis

References

• Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26:1816–1821. doi:10.1177/1352458520970841
   PubMed Web of Science ®Google Scholar
• Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: a Review. Am J Med. 2020;133:1380–1390 e1382. doi:10.1016/j.amjmed.2020.05.049
   PubMed Web of Science ®Google Scholar
• Lublin FD, Häring DA, Ganjgahi H, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145:3147–3161. doi:10.1093/brain/awac016
   PubMed Web of Science ®Google Scholar
• Vukusic S, Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol. 2007;20:269–274. doi:10.1097/WCO.0b013e32812583ad
   PubMed Web of Science ®Google Scholar
• Yang JH, Rempe T, Whitmire N, et al. Therapeutic Advances in Multiple Sclerosis. Front Neurol. 2022;13:824926. doi:10.3389/fneur.2022.824926
   PubMed Web of Science ®Google Scholar
• Tedeholm H, Piehl F, Lycke J, et al. Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis. Mult Scler Relat Disord. 2022;68:104220. doi:10.1016/j.msard.2022.104220
   PubMed Web of Science ®Google Scholar
• McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis A Review. JAMA-J Am Med Assoc. 2021;325:765–779. doi:10.1001/jama.2020.26858
   PubMed Web of Science ®Google Scholar
• Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019;15:287–300. doi:10.1038/s41582-019-0170-8
   PubMed Web of Science ®Google Scholar
• Van Wijmeersch B, Hartung HP, Vermersch P, et al. Using personalized prognosis in the treatment of relapsing multiple sclerosis: a practical guide. Front Immunol. 2022;13:ARTN 991291. doi:10.3389/fimmu.2022.991291
   Web of Science ®Google Scholar
• Hoffmann O, Gold R, Meuth SG, et al. Prognostic relevance of MRI in early relapsing multiple sclerosis: ready to guide treatment decision making? Ther Adv Neurol Disord. 2024;17:17562864241229325. doi:10.1177/1756286424122932
   Google Scholar
• Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9(Suppl 1):S5–S48. doi:10.1016/j.msard.2016.07.003
   PubMed Web of Science ®Google Scholar
• Weideman AM, Tapia-Maltos MA, Johnson K, et al. Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments. Front Neurol. 2017;8:ARTN 577. doi:10.3389/fneur.2017.00577
   Web of Science ®Google Scholar
• Wiendl H, Gold R, Berger T, et al. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Diso. 2021;14:Artn 17562864211039648. doi:10.1177/17562864211039648
   Web of Science ®Google Scholar
• Burks J, Marshall TS, Ye XL. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. Clinicoeconomic Outc. 2017;9:251–260. doi:10.2147/Ceor.S130334
   PubMed Web of Science ®Google Scholar
• Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18:69–77. doi:10.1111/j.1468-1331.2010.03110.x
   PubMed Web of Science ®Google Scholar
• Bischoff C, Schreiber H, Bergmann A. Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment. J Neurol. 2012;259:2347–2353. doi:10.1007/s00415-012-6499-1
   PubMed Web of Science ®Google Scholar
• Klotz L, Havla J, Schwab N, et al. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord. 2019;12:1756286419836571. doi:10.1177/1756286419836571
   Web of Science ®Google Scholar
• Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol. 2008;255(Suppl 6):87–92. doi:10.1007/s00415-008-6016-8
   PubMed Web of Science ®Google Scholar
• Visser LA, Louapre C, Uyl-de Groot CA, Redekop WK. Patient needs and preferences in relapsing-remitting multiple sclerosis: a systematic review. Mult Scler Relat Disord. 2020;39:101929. doi:10.1016/j.msard.2020.101929
   PubMed Web of Science ®Google Scholar
• Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018;25:215–237. doi:10.1111/ene.13536
   PubMed Web of Science ®Google Scholar
• Rae-Grant A. Author response: practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2019;92:110–111. doi:10.1212/WNL.0000000000006735
   PubMed Web of Science ®Google Scholar
• Eskyte I, Manzano A, Pepper G, et al. Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: a critical interpretive synthesis. Mult Scler Relat Dis. 2019;27:370–377. doi:10.1016/j.msard.2018.11.016
   PubMed Web of Science ®Google Scholar
• Muller S, Ziemssen T, Diehm C, et al. How to Implement Adherence-Promoting Programs in Clinical Practice? A Discrete Choice Experiment on Physicians’ Preferences. Patient Prefer Adherence. 2020;14:267–276. doi:10.2147/PPA.S222725
   PubMed Web of Science ®Google Scholar
• Lugaresi A, Ziemssen T, Oreja-Guevara C, et al. Improving patient-physician dialog: commentary on the results of the MS Choices survey. Patient Prefer Adherence. 2012;6:143–152. doi:10.2147/PPA.S27932
   PubMed Web of Science ®Google Scholar
• Bharmal M, Payne K, Atkinson MJ, et al. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7: 36:20090427. doi:10.1186/1477-7525-7-36
   Web of Science ®Google Scholar
• Ware JE, Sherbourne CD. The Mos 36-Item Short-Form Health Survey (Sf-36).1. Conceptual-Framework and Item Selection. Med Care. 1992;30:473–483. doi:10.1097/00005650-199206000-00002
   PubMed Web of Science ®Google Scholar
• Greiner W, Claes C, Busschbach JJ, von der Schulenburg JM. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ. 2005;6:124–130. doi:10.1007/s10198-004-0264-z
   PubMedGoogle Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452. doi:10.1212/wnl.33.11.1444
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Kern R, Voigt I, Haase R. Data Collection in Multiple Sclerosis: the MSDS Approach. Front Neurol. 2020;11:445. doi:10.3389/fneur.2020.00445
   PubMedGoogle Scholar
• Kass GV. An Exploratory Technique for Investigating Large Quantities of Categorical Data. J Royal Statistical Soc. 1980;29:119–127. doi:10.2307/2986296
   Google Scholar
• Braune S, Rossnagel F, Dikow H, et al. Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry. BMJ Open. 2021;11:e042480. doi:10.1136/bmjopen-2020-042480
   PubMed Web of Science ®Google Scholar
• Reen GK, Silber E, Langdon DW. Multiple sclerosis patients’ understanding and preferences for risks and benefits of disease-modifying drugs: a systematic review. J Neurol Sci. 2017;375:107–122. doi:10.1016/j.jns.2016.12.038
   PubMed Web of Science ®Google Scholar
• Haase R, Kullmann JS, Ziemssen T. Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey. Ther Adv Neurol Disord. 2016;9:250–263. doi:10.1177/1756285616634247
   PubMed Web of Science ®Google Scholar
• Brex PA, Ciccarelli O, O’Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346:158–164. doi:10.1056/NEJMoa011341
   PubMed Web of Science ®Google Scholar
• Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131:808–817. doi:10.1093/brain/awm329
   PubMed Web of Science ®Google Scholar
• Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol. 2006;60:236–242. doi:10.1002/ana.20883
   PubMed Web of Science ®Google Scholar
• Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20:653–670. doi:10.1016/S1474-4422(21)00095-8
   PubMed Web of Science ®Google Scholar
• Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol. 2002;15:239–245. doi:10.1097/00019052-200206000-00003
   PubMed Web of Science ®Google Scholar
• Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology. 1995;45:255–260. doi:10.1212/wnl.45.2.255
   PubMed Web of Science ®Google Scholar
• Bielekova B, Tintore M. Sustained reduction of MS disability: new player in comparing disease-modifying treatments. Neurology. 2016;87:1966–1967. doi:10.1212/WNL.0000000000003314
   PubMed Web of Science ®Google Scholar
• Bauer B, Brockmeier B, Devonshire V, et al. An international discrete choice experiment assessing patients’ preferences for disease-modifying therapy attributes in multiple sclerosis. Neurodegener Dis Manag. 2020;10:369–382. doi:10.2217/nmt-2020-0034
   PubMed Web of Science ®Google Scholar
• Wilson LS, Loucks A, Gipson G, et al. Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis. Int J MS Care. 2015;17:74–82. doi:10.7224/1537-2073.2013-053
   PubMedGoogle Scholar
• Tintoré M, Alexander M, Costello K, et al. The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction. Patient Prefer Adher. 2017;11:33–45. doi:10.2147/Ppa.S115090
   PubMed Web of Science ®Google Scholar
• Kremer IEH, Evers S, Jongen PJ, Hiligsmann M. Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: a best-worst scaling. Health Expect. 2018;21:171–180. doi:10.1111/hex.12599
   PubMed Web of Science ®Google Scholar
• de Seze J, Borgel F, Brudon F. Patient perceptions of multiple sclerosis and its treatment. Patient Prefer Adher. 2012;6:263–273. doi:10.2147/Ppa.S27038
   PubMed Web of Science ®Google Scholar
• Kopke S, Solari A, Rahn A, et al. Information provision for people with multiple sclerosis. Cochrane Database Syst Rev. 2018;10:CD008757. doi:10.1002/14651858.CD008757.pub3
   PubMedGoogle Scholar
• Burkhard A, Toliver J, Rascati K. Association between multiple sclerosis disease severity and adherence to disease-modifying therapies. J Manag Care Spec Ph. 2021;27:915–923. doi:10.18553/jmcp.2021.27.7.915
   PubMed Web of Science ®Google Scholar
• Ben-Zacharia AB, Walker B, Ross AP, et al. Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: a Scoping Literature Review. Int J MS Care. 2023;25:188–195. doi:10.7224/1537-2073.2021-139
   PubMedGoogle Scholar
• Hansen K, Schussel K, Kieble M, et al. Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: a Retrospective Cohort Study. PLoS One. 2015;10:e0133279. doi:10.1371/journal.pone.0133279
   PubMed Web of Science ®Google Scholar
• Schriefer D, Haase R, Kullmann JS, Ziemssen T. Health-Related Quality of Life and the Relationship to Treatment Satisfaction in Patients with Multiple Sclerosis: insights from a Large Observational Study. Patient Prefer Adherence. 2020;14:869–880. doi:10.2147/PPA.S248272
   PubMed Web of Science ®Google Scholar
• Donze C, Malapel L, Kwiatkowski A, et al. Treatment discontinuation in multiple sclerosis: the French Web-based survey ALLIANCE. Mult Scler J Exp Transl Clin. 2015;1:2055217315600720. doi:10.1177/2055217315600720
   Google Scholar
• Andersen JR, Aasprang A, Karlsen TI, et al. Health-related quality of life after bariatric surgery: a systematic review of prospective long-term studies. Surg Obes Relat Dis. 2015;11:466–473. doi:10.1016/j.soard.2014.10.027
   PubMed Web of Science ®Google Scholar
• Greene N, Quere S, Bury DP, et al. Establishing clinically meaningful within-individual improvement thresholds for eight patient-reported outcome measures in people with relapsing-remitting multiple sclerosis. J Patient Rep Outcomes. 2023;7:61. doi:10.1186/s41687-023-00594-8
   PubMedGoogle Scholar
• Heesen C, Haase R, Melzig S, et al. Perceptions on the value of bodily functions in multiple sclerosis. Acta Neurol Scand. 2018;137:356–362. doi:10.1111/ane.12881
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Popescu V, Wuerfel J, et al. Smouldering multiple sclerosis: the ‘real MS’. Ther Adv Neurol Disord. 2022;15:17562864211066751. doi:10.1177/17562864211066751
   Web of Science ®Google Scholar
• Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 2020;77:1132–1140. doi:10.1001/jamaneurol.2020.1568
   PubMed Web of Science ®Google Scholar